All In Biotech

Free tool

FAERS Monitor: Litfulo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215830 or its brand name (Litfulo, Ritlecitinib Tosylate). Reports on generic versions are filed under their own applications.

Reports

1,963

Serious

398

20% of reports

Hospitalization

106

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective346
  • therapeutic product effect incomplete135
  • condition aggravated120
  • off label use109
  • headache91
  • alopecia66
  • diarrhoea66
  • urticaria55
  • product dose omission issue51
  • pruritus50
  • fatigue45
  • acne44
  • rash44
  • nausea40
  • dizziness36

Reports by year received

View as table
YearReports
20191
20222
2023156
2024722
2025771
2026311

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,196 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
therapeutic product effect incompleteSignal13520.417.32,471
acneSignal446.24.6188
condition aggravatedSignal1204.23.6297
alopeciaSignal663.62.8123
urticariaSignal553.52.797
drug ineffectiveSignal3462.82.6429
product dose omission issue511.91.420
headache911.61.318
pruritus501.41.15
off label use1091.31.19
diarrhoea661.10.90
rash441.10.80
dizziness360.80.62
fatigue450.60.511
nausea400.50.416

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.